



Halozyme Therapeutics, Inc.



HALO NASDAQ

Biotechnology

Market Capitalization USD:

\$636.22 mm

CONCERN LEVEL: LOW

- 1 The CEO's total remuneration is within the typical market range for the relevant industry and market cap.
- 2 The ratio between the CEO's pay and the median pay of the other named executive officers is 3X or less.
- 3 The CEO's annual cash incentives rose or fell in line with annual performance. 
- 4 The CEO received no more than one annual cash bonus this fiscal year.
- 5 The CEO's equity remuneration reflected the company's share price movement over the last five years.
- 6 The company only pays long-term incentives to the CEO for above median performance against a peer group.
- 7 The company's dilution from equity incentives is 10 percent or less.
- 8 Unvested equity lapses when the CEO's employment is terminated. 
- 9 The CEO's potential cash severance payment is capped at two times annual cash remuneration.
- 10 The accrued benefits of the CEO's post-retirement income are within the typical market range for the relevant market cap bracket.

CEO: Gregory I. Frost

Age: 40

CEO Since: 2010

	2009	2010	2011
Base Salary	\$395,000	\$383,597	\$415,000
Discretionary Bonus	\$0	\$0	\$0
Annual Cash Incentive	\$12,063	\$0	\$80,000
Benefits and Perquisites	\$7,717	\$490,580	\$7,788
TOTAL ANNUAL COMPENSATION	\$414,780	\$874,177	\$502,788
Increase in Post-Retirement Benefits	\$0	\$0	\$0
Stock Option Awards	\$422,268	\$420,720	\$7,316
Stock Awards	\$0	\$0	\$173,420
TOTAL COMPENSATION	\$837,048	\$1,294,897	\$683,524
Median of Other Named Executive Officers Total Compensation	\$814,946	\$621,040	\$871,146
Value Realized on Exercise of Stock Option	\$0	\$163,800	\$0
Value Realized on Vesting of Stock	\$0	\$0	\$0
TOTAL REALIZED EQUITY COMPENSATION	\$0	\$163,800	\$0

Proxy Date: 29 Mar 2012

Annual Meeting Date: 3 May 2012

Equity Reserves: 9.72%

Stock Option Run Rate: 1.33%

Halozyyme Therapeutics, Inc.


HALO NASDAQ

Biotechnology

Market Capitalization USD: **\$636.22 mm**

Performance Comparison

■ S&P500 ■ Industry ■ HALO



Peer Comparisons (TRBC) =Biotechnology

Total Summary CEO Compensation

Ticker	Company Name	2009	2010	2011	Market Cap
HALO	Halozyyme Therapeutics, Inc.	\$837,048	\$1,294,897	\$683,524	\$636,224,614
ONXX	ONYX Pharmaceuticals, Inc.	\$4,136,535	\$3,904,151		\$1,906,972,785
INCY	Incyte Corporation	\$1,504,386	\$2,170,699		\$1,763,568,189
JAZZ	Jazz Pharmaceuticals, Inc.	\$838,863	\$1,929,028		\$1,732,180,078
CRL	Charles River Laboratories International, Inc.	\$5,251,246	\$4,758,965		\$1,469,877,722
VPHM	ViroPharma Incorporated	\$1,754,879	\$2,403,480		\$1,372,311,422
DNDN	Dendreon Corporation	\$3,807,413	\$5,254,373		\$1,339,719,318

To insure consistency, peer comparisons are based on a combination of TRBC Industry and Sector classifications and company market caps.

Missing peer pay figures for 2011 are due to differences in company filing schedules.

Pay Peer Group

NA

Performance Peer Group

NA

COMPENSATION COMMITTEE MEMBERS

Director	Membership	Age	Gender	Tenure	Independence
Connie L. Matsui	Chairman	58	Female	6	Outside
John S. Patton	Member	65	Male	12	Outside Related
Kathryn E. Falbera	Member	51	Female	5	Outside

This report is for informational purposes only, and should not be considered a solicitation to buy or sell any security. Thomson Reuters Business Classification (TRBC) is a global industry classification system that is owned and operated by Thomson Reuters and has been licensed for use by GMI Ratings.

COPYRIGHT 2012 | GMI Ratings | ALL RIGHTS RESERVED